Catalyst Pharmaceuticals CEO to Speak at Piper Sandler Healthcare Conference
Coral Gables, Florida – Patrick J. McEnany, the Chairman and CEO of Catalyst Pharmaceuticals, Inc. (Catalyst), is scheduled to speak at the upcoming Piper Sandler Healthcare Conference. This event, taking place at the Lotte New York Palace hotel, is an opportunity for Catalyst to showcase its achievements in the biopharmaceutical industry.
Catalyst Pharmaceuticals is a commercial-stage company dedicated to developing and commercializing groundbreaking medicines for individuals with rare diseases. With a strong focus on patients, Catalyst aims to address the unmet needs of those living with neurological and epileptic conditions.
One of Catalyst’s notable products is FIRDAPSE, an approved treatment for Lambert-Eaton myasthenic syndrome (LEMS) in both adult and pediatric patients. Additionally, Catalyst acquired the U.S. commercial rights to FYCOMPA, a prescription medicine approved for the treatment of partial-onset seizures in individuals aged four and older with epilepsy. Catalyst’s commitment to rare diseases also extends to Duchenne Muscular Dystrophy, as the company obtained an exclusive license for AGAMREE, a novel corticosteroid treatment.
During the Piper Sandler Healthcare Conference, Patrick J. McEnany and other members of Catalyst’s management team will engage in 1×1 meetings and participate in a fireside discussion at 10:30 am ET on Wednesday, November 29, 2023. This platform allows them to share insights into Catalyst’s innovative research and development efforts and foster collaboration within the healthcare industry.
Catalyst Pharmaceuticals emphasizes its dedication to advancing the treatment options available to individuals with rare diseases. By participating in conferences like the Piper Sandler Healthcare Conference, Catalyst aims to strengthen its position as a leading biopharmaceutical company. With a promising pipeline of novel medicines, the company is poised to make a significant impact on the lives of patients living with rare neurological and epileptic conditions.
For more information about Catalyst Pharmaceuticals, Inc., visit their website at www.catalystpharma.com.
